Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study

BACKGROUND: Large-scale screening for atrial fibrillation (AF) requires reliable methods to identify at-risk populations. Using an experimental semi-quantitative biomarker assay, B-type natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF23) were recently identified as the most suitable bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Winnie, Law, Jonathan P., Cardoso, Victor R., Purmah, Yanish, Neculau, Georgiana, Jawad-Ul-Qamar, Muhammad, Russell, Kalisha, Turner, Ashley, Tull, Samantha P., Nehaj, Frantisek, Brady, Paul, Kastner, Peter, Ziegler, André, Gkoutos, Georgios V., Pavlovic, Davor, Ferro, Charles J., Kirchhof, Paulus, Fabritz, Larissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857735/
https://www.ncbi.nlm.nih.gov/pubmed/33534825
http://dx.doi.org/10.1371/journal.pmed.1003405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857735/
https://www.ncbi.nlm.nih.gov/pubmed/33534825
http://dx.doi.org/10.1371/journal.pmed.1003405

Ejemplares similares